Navigation Links
FDA Requires Sybaritic, Inc. to Stop Producing Unapproved Medical Devices
Date:1/8/2010

SILVER SPRING, Md., Jan. 8 /PRNewswire-USNewswire/ -- Sybaritic Inc., a medical device maker, has agreed to stop producing and distributing its medical products used in laser surgery, dermatology, and spa treatments until it is in compliance with FDA quality standards. The products are considered to be unapproved medical devices as they lack appropriate FDA clearance review and approval for safety and effectiveness. The agreement was part of a consent decree of injunction signed by the Bloomington, Minn., company and three of its top executives, Anthony S. Daffer, Steven J. Daffer, and Ronald Berglund.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

"This action halts the manufacture of these products until the manufacturer comes into compliance with federal law," said Jeffrey Shuren, M.D., J.D., acting director of the FDA's Center for Devices and Radiological Health. "It's critical that companies comply with laws that are in place to protect consumer health."

Under the terms of the consent decree, Sybaritic agrees to comply with the FDA's Quality System (QS) regulation for all of its devices. Sybaritic also must retain an independent expert consultant to inspect its operations and to certify to the FDA that corrections have been made.

Sybaritic designs, manufactures and distributes a variety of medical devices including moist steam cabinets (Dermalife products such as Hydration Station, Spa Oceana, Spa Jet, and Spa Fengshui), laser systems (NannoLight MP50, LaserPeel Trimatrixx, SkinClear SRVH), ultrasound and non-invasive subdermal therapy systems (Dermosonic), and microdermabrasion systems (SkinBella).

The SkinBella has never been approved or cleared by the FDA. The Dermalife, NannoLight MP50, SkinClear SRVH, and the Dermosonic devices are unapproved because, although the devices have FDA clearance for marketing, Sybaritic has made claims for these devices that are not included in the FDA clearances and constitute major changes or modifications in the devices' intended use. Sybaritic has also made subsequent changes to some of these devices' designs that are not included in the clearances and that could significantly impact their safety and effectiveness.

FDA inspections conducted at Sybaritic over the past several years, and most recently in March 2009, revealed violations of the agency's QS regulation, including violations related to design controls, complaint handling, corrective and preventive action, and quality audits. These inspections also revealed the company's sale of numerous devices that had not undergone the required FDA premarket review as well as the company's failure to submit medical device reports to the agency as required.

The consent decree requires Sybaritic to obtain appropriate FDA approval or clearance before it may distribute any of its devices. Once Sybaritic makes the corrective actions specified in the consent decree, it must hire an independent auditor to conduct annual inspections of all its facilities for at least four years and report the results to the FDA.

In the event of future violations at Sybaritic, the consent decree allows FDA to order Sybaritic to cease manufacturing and distributing products and to recall them. FDA can take other actions to ensure Sybaritic is compliant with FDA regulations. The company may be required to pay damages of $15,000 a day if it fails to comply with any provisions of the decree and an additional $15,000 for each violation.

The FDA is not aware of any adverse events, but is advising consumers to discontinue using these products.

The consent decree was signed on Jan. 4, 2010, by U.S. District Court Judge John R. Tunheim of the U.S. District Court for the District of Minnesota.

FDA's Web site on Laser Facts:

http://www.fda.gov/Radiation-EmittingProducts/ResourcesforYouRadiationEmittingProducts/Consumers/ucm142607.htm

Media Inquiries: Peper Long, 301-796-4671, mary.long@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

RELATED LINKS
http://www.fda.gov/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Effective Pain Management Requires an Interdisciplinary Approach
2. American Medical Womens Association Supports New Bill That Requires Medicare Coverage of HPV Testing as Part of Cervical Cancer Screening
3. Vermont Requires Reporting of NQF Serious Reportable Events
4. Justice Department Requires Divestitures in Pearsons Acquisition of Harcourt Assessment
5. Growing Importance of March 4 Texas Primary Requires 2008 Presidential Candidates to Better Address Eldercare Financing Issues
6. Aetna Requires CAQH Core Rules Certification for Vendors
7. Justice Department Requires Divestiture in UnitedHealth Groups Acquisition of Sierra Health Services
8. Study finds that competency in colonoscopy requires experience with 150 cases or more
9. Improving Access to Safe Water, Sanitation, Hygiene Requires Better Decision-Making Tools, Finds Joint Wilson Center-Pacific Institute Report
10. TB treatment for the elderly likely requires a boost to immune response
11. Solving California Nursing Shortage Requires Redesigned Education System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology: